Viridian Therapeutics, Inc.

Viridian Intersects 15m of 1.1% CuEq in 1.5km Step-Out Drilling at Kraken Main

Viridian Metals reported first assays from its southern step-out program at Kraken, intersecting 15.05 metres at 1.09% CuEq within 40.8 metres at 0.63% CuEq about 1.5 km south of prior drilling. Both holes were mineralized from the top of bedrock to end of hole, with intercepts exceeding 30 metres — more than three times the 8.6-metre average thickness underpinning the initial Exploration Target. Assays remain pending from visually identified sulphide intervals of 41.8 and 47.3 metres along a further 2.5 km of strike, with updated Exploration Target expected in January 2027 — positive catalysts, though no mineral resource has yet been defined.

•9d ago

Viridian Intersects Sulphides Throughout 3 km of Step-Out Drilling at Kraken Main

Viridian Metals drilled sulphides in all eight step-out holes along a 3 km southern extension of the Kraken Main Zone in Labrador, with broad intervals including 47.3 metres of net-textured sulphides. Visual sulphides start at the top of bedrock and remain open at depth in several holes; laboratory assays confirming grades are expected before the end of October. Separately, the company engaged Oak Hill Financial for investor relations at C$12,000/month and announced its shares are now DTC eligible, which should improve US trading liquidity. All step-out mineralization remains visually identified and unconfirmed by assays, so results are preliminary pending lab analysis.

•0mo ago

Viridian Announces Initial Exploration Target at Kraken Main Zone

Viridian Metals published an initial Exploration Target for Kraken Main of 41 to 61 million tonnes grading 0.35% to 0.52% copper equivalent, the first quantified framework for its 100%-owned Kraken copper-nickel-cobalt project in Labrador. The target is conceptual: it uses only pre-2026 drilling, an 8.6-metre modelled average mineralized thickness and an untested 80% recovery assumption, and the company cautions there is no guarantee it converts into a Mineral Resource. Only four of more than 60 geophysical conductors at Kraken have been drill tested, all intersecting magmatic sulphide mineralization, and new overlimit assays from hole VKS26-054 returned intervals up to 2.18% CuEq — none of which is captured in the target. Separately, Viridian signed a six-month C$150,000 marketing services agreement with Outside The Box Capital for retail-investor outreach across Reddit, Discord, X and other platforms, with 214,286 options granted at C$0.70 per share.

•1mo ago

Viridian Intersects Over 50 Metres of Mineralization from Surface at Kraken Main

Viridian Metals reported 50.15 metres of mineralization grading 0.68% CuEq starting at surface at the Kraken Main Zone in Labrador, after extending hole VKS25-024 to 51.15 metres. The extension more than doubles the previously reported 24.05-metre interval and includes 18.8 metres at 1.12% CuEq; CEO Tyrell Sutherland said mineralization begins at surface and continues beyond 50 metres depth, adding volume potential across the zone. Three large step-outs drilled roughly 600 metres, 900 metres and 1.2 kilometres from previous drilling all hit visually identified semi-massive sulphides at the top of bedrock, with assays pending; two rigs will drill through the end of October while the company finalizes an initial Kraken Main exploration target.

•1mo ago

Viridian Reports Continuation of Massive Sulphides at Kraken Main; First Assays Pending

Viridian Metals reported visual observations from the 2026 drill program at the Kraken project, specifically regarding the extension of hole VKS25-024 which previously ended in mineralization. Massive to semi-massive sulphides were observed to continue for approximately 33 metres, transitioning to patchy net-textured sulphides to a final depth of 51 metres. Analytical results from the first submission are expected in the coming weeks, though the company cautioned that visual observations are preliminary and not a substitute for laboratory assays.

•2mo ago

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Viridian Therapeutics has transitioned to a commercial-stage company following the FDA approval and immediate U.S. launch of Lumvoa for thyroid eye disease on June 26, 2026. Early launch metrics indicate strong engagement, with the sales team reaching 95% of core prescribers and positive payer adoption efforts underway. For the second quarter of 2026, the company reported total revenue of $284,000 and a net loss of $127.1 million, with R&D expenses decreasing year-over-year to $71.6 million while SG&A increased to $55.0 million to support the commercial rollout. The balance sheet remains robust with $981.5 million in cash and securities following a May financing, sufficient to fund operations through profitability. Pipeline progress continues, with a BLA submission for the subcutaneous therapy Elegrobart targeted for Q1 2027 and an IND submission for the TSHR program anticipated in Q4 2026.

•2mo ago

Viridian Metals Commences Trading on the OTCQB Venture Market Under the Symbol “VIRMF”

Viridian Metals shares commenced trading on the OTCQB Venture Market under the symbol VIRMF, extending the company's reach into U.S. capital markets. The listing is expected to provide practical advantages such as U.S. dollar trading during market hours and enhanced market data for shareholders. Viridian has also submitted an application for DTC eligibility to facilitate electronic share transfers between U.S. brokerage accounts.

•3mo ago

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

The FDA approved Viridian Therapeutics' Lumvoa for the treatment of thyroid eye disease, marking the company's first commercial product launch. Approval was supported by data from the THRIVE and THRIVE-2 pivotal Phase 3 trials, which demonstrated rapid and consistent reductions in proptosis and diplopia across both active and chronic patient populations. Viridian plans to launch Lumvoa immediately with a comprehensive patient support program, while its subcutaneous therapy elegrobart remains on track for a BLA submission in Q1 2027.

•4mo ago

Viridian Metals Highlights Copper-Rich Zones up to 4.15% Cu at Kraken Ahead of 2026 Drill Program

Viridian Metals is advancing its 2026 exploration program at the Kraken magmatic sulphide system in Labrador, targeting high-grade copper zones identified in 2024 drilling. The upcoming 50-hole drill program aims to systematically follow up on zones that previously intersected copper grades up to 4.15% Cu, while also expanding the Main Zone footprint. The company also highlighted the Venus target, ~8km south of the Main Zone, which remains largely untested but showed massive sulfides and precious metal values in prior holes.

•4mo ago

Viridian Metals Announces Flow-Through Private Placement, Warrant Extension and Date of Annual General and Special Meeting

Viridian Metals announced a non-brokered private placement of flow-through units raising $750,000 at $0.52 per unit, a 60% premium to the May 13 closing price. The investor is Pavilion Flow-Through L.P., a fund managed by Accilent Capital Management. Upon closing, Accilent will control approximately 20.84% of outstanding shares, becoming a new 'Control Person' under CSE rules. The transaction requires shareholder approval at a special meeting on June 22, 2026. The company also extended the expiry of 2.22 million existing warrants by one year to May 23, 2027, with an unchanged exercise price of $0.45.

•5mo ago

Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Viridian Therapeutics confirmed launch readiness for veligrotug, which has a PDUFA target action date of June 30, 2026, and reported positive topline data from the REVEAL-1 and REVEAL-2 Phase 3 trials for subcutaneous elegrobart. Q1 financial results showed a net loss of $104.9 million, with R&D expenses of $77.6 million and SG&A expenses rising to $38.7 million due to commercial launch preparations. The company holds $762.2 million in cash and investments as of March 31, 2026, and plans to submit a BLA for elegrobart in Q1 2027.

•5mo ago

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease

Viridian Therapeutics announced positive topline results from the Phase 3 REVEAL-2 trial of elegrobart in chronic thyroid eye disease (TED), meeting its primary endpoint with high statistical significance. The trial reported proptosis responder rates of 50% and 54% for the Q4W and Q8W dosing regimens, respectively, compared to 15% for placebo, with Q4W also achieving a statistically significant diplopia responder rate of 61%. Based on the data, the company remains on track to submit a Biologics License Application (BLA) for elegrobart in Q1 2027, while its lead program veligrotug maintains a PDUFA target action date of June 30, 2026.

•5mo ago